Author

Sina Federmann

Düsseldorf University Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Gerhard FritziD· 2 shared Andreas S. ReichertiD· 1 shared Elvira Mukinovic· 1 shared Julia Mann· 1 shared Larissa Messling· 1 shared Lena Abbey· 1 shared Marlena Sekeres· 1 shared Matthias Ulrich KassackiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

9 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Gerhard FritzORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Differential responses of murine embryonic stem cells (mESC) and their endothelial progeny to doxorubicin and pharmacological inhibitors of DNA repair and DNA damage response

Sina Federmann, Michelle Westerhoff, Andreas S. Reichert, Gerhard Fritz

This study compares the response of murine embryonic stem cells and their endothelial progeny to doxorubicin and DNA repair inhibitors, finding differential susceptibility and functional impairments in differentiated cells.

bioRxiv · May 15, 2025 · PreprintPharmacology & Toxicology

Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil-mediated promotion of DNA damage-driven cell death

Elvira Mukinovic, Sina Federmann, Larissa Messling, Marlena Sekeres, Julia Mann, Lena Abbey, Matthias Ulrich Kassack, Gerhard Fritz

This study identifies verapamil as a synergistic agent to overcome doxorubicin resistance in ovarian cancer cells by enhancing DNA damage and apoptosis.

bioRxiv · Apr 23, 2025 · PreprintPharmacology & Toxicology